2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK Cytoskeleton Cell Cycle/DNA Damage
  3. Antibody-Drug Conjugates (ADCs) c-Met/HGFR Microtubule/Tubulin
  4. Telisotuzumab vedotin

Telisotuzumab vedotin  (Synonyms: ABBV-399)

Cat. No.: HY-141601 Purity: 99.26%
COA
SDS
Handling Instructions Technical Support

Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research.

For research use only. We do not sell to patients.

CAS No. : 1714088-51-3

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Telisotuzumab vedotin Related Antibodies

Top Publications Citing Use of Products
In Vivo Efficacy Study
In Vivo Imaging

    Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688.

    Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Telisotuzumab vedotin, 10 nmol/kg)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm3) (n = 5∼7/group).

    Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688.

    Bioluminescence imaging of mice with orthotopic pancreatic tumors treated with B6ADC or the combination of "SG and Telisotuzumab vedotin (10 nmol/kg)" for 28 days (n = 4/group).

    Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688.

    Survival curves of mice treated with B6ADC or SG+Telisotuzumab vedotin (10 nmol/kg). Survival analysis was performed using the Kaplan-Meier method, and statistical significance was determined by the log rank (Mantel-Cox) test.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research[1][2][3].

    In Vitro

    ABBV-399 demonstrates potent cytotoxicity that is dependent on a threshold level of target expression and is not reliant on inhibiting MET signaling in tumor cell lines with high c-Met expression or MET amplification[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Telisotuzumab vedotin Related Antibodies
    In Vivo

    ABBV-399 effectively inhibits tumor growth and overcomes resistance to small molecule MET inhibitors in xenograft models resistant to other c-Met inhibitors[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    145000 (average)

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Telisotuzumab vedotin]
    Shipping

    Shipping with dry ice.
    Storage

    -80°C, protect from light
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL

    *"≥" means soluble, but saturation unknown.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation

    Purity: 99.81%

    SDS (251 KB)

    COA (231 KB) Others (381 KB) SEC-HPLC (370 KB)

    Handling Instructions (2659 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Telisotuzumab vedotin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Telisotuzumab vedotin1714088-51-3ABBV-399ABBV399ABBV 399Antibody-Drug Conjugates (ADCs)c-Met/HGFRMicrotubule/TubulinAntibody-Drug ConjugatesNon-Small Cell Lung CancertumorADCInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Telisotuzumab vedotin
    Cat. No.:
    HY-141601
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.